Otonomy, Inc. (OTIC) Stock Rating Lowered by Piper Jaffray Companies
Otonomy, Inc. (NASDAQ:OTIC) was downgraded by investment analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research note issued to investors on Wednesday.
Other research analysts have also issued reports about the stock. J P Morgan Chase & Co lowered shares of Otonomy from an “overweight” rating to a “neutral” rating and set a $8.00 price target on the stock. in a research note on Wednesday. BidaskClub lowered shares of Otonomy from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Cowen and Company reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Otonomy in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research raised shares of Otonomy from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $27.50.
Shares of Otonomy (NASDAQ OTIC) traded down 81.49% during mid-day trading on Wednesday, hitting $3.85. The company’s stock had a trading volume of 37,170,847 shares. The stock’s 50 day moving average price is $18.78 and its 200 day moving average price is $15.30. Otonomy has a 52-week low of $3.45 and a 52-week high of $20.90. The company’s market cap is $116.67 million.
Otonomy (NASDAQ:OTIC) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.03. Otonomy had a negative net margin of 8,172.38% and a negative return on equity of 57.43%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.43 million. During the same period in the prior year, the company posted ($0.98) EPS. The company’s revenue for the quarter was up 312.5% on a year-over-year basis. Equities analysts forecast that Otonomy will post ($3.36) EPS for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/otonomy-inc-otic-stock-rating-lowered-by-piper-jaffray-companies/1532152.html.
In other Otonomy news, insider Eric J. Loumeau sold 3,522 shares of the stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $18.59, for a total value of $65,473.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.70% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Otonomy during the second quarter worth approximately $115,000. Legal & General Group Plc increased its stake in Otonomy by 13.3% in the second quarter. Legal & General Group Plc now owns 6,348 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 746 shares during the last quarter. Trexquant Investment LP acquired a new stake in Otonomy during the first quarter worth approximately $123,000. American International Group Inc. increased its stake in Otonomy by 7.1% in the first quarter. American International Group Inc. now owns 14,800 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 981 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in Otonomy during the first quarter worth approximately $216,000. Institutional investors own 88.74% of the company’s stock.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.